Interferon News and Research

RSS

Early treatment for hepatitis C offers a good chance of a cure

Australian researchers say as many as 70% of hepatitis C carriers can possibly be cured of the disease with early treatment - this is excellent news as hepatitis C, if left untreated can lead to serious liver disease.

22 Apr 2009

New updated clinical guidelines for HIV-associated opportunistic infections

The first complete update in five years of the U.S. guidelines for preventing and treating HIV-associated opportunistic infections has been released by the National Institutes of Health and the Centers for Disease Control and Prevention in cooperation with the HIV Medicine Association of the Infectious Diseases Society of America (IDSA).

16 Apr 2009

Tijuana injection drug users on collision course for HIV and tuberculosis

A study by researchers from the University of California, San Diego School of Medicine, in collaboration with Mexican researchers and health officials, shows that as many as 67 percent of injection drug users in Tijuana test positive for tuberculosis (TB) infection.

15 Apr 2009

Research looks at the elimination of hepatitis B and C

Two new studies in the April issue of Hepatology explore the ways that hepatitis B virus (HBV) and hepatitis C virus (HCV) can be cleared from patients' bodies.

1 Apr 2009

Mutations within a conservative region of hepatitis C virus affect therapy

At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide.

30 Mar 2009

Potential therapeutic strategy for fulminant hepatic failure

Fulminant hepatic failure is a serious clinical disease and may threaten the life of patients. However, because of the damage of mass liver cells, the organ function is often irreversible due to the liver cell degeneration, swelling, or apoptosis.

30 Mar 2009

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics has announced that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial were presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

29 Mar 2009

Helix BioPharma receives approval to start phase II study of topical interferon alpha-2b in low-grade cervical lesions

Helix BioPharma Corp. announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

16 Mar 2009

Stem cells could halt osteoporosis, promote bone growth

While interferon gamma sounds like an outer space weapon, it's actually a hormone produced by our own bodies, and it holds great promise to repair bones affected by osteoporosis.

4 Mar 2009

New discovery improves efficacy of current tuberculosis vaccine

A new article appearing in the March 2009 issue of the Journal of Leukocyte Biology may lead to improvements in the efficacy of the current tuberculosis vaccine.

26 Feb 2009

Liver transplant recipients with hepatitis B may need lifelong antiviral treatment

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back.

26 Feb 2009

New cancer treatment stops aggressive sarcomas

After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.

25 Feb 2009

New approaches to prevent transplant rejection

To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems.

15 Feb 2009

Oncostatin M may be a promising drug for treating viral hepatitis and liver cancer

This research, coordinated by the doctors Jesús Prieto, Esther Larrea, Pablo Sarobe, Iranzu González and Rafael Aldabe, has been published in the Journal of Virology ; a journal of the American Society of Microbiology.

9 Feb 2009

Research to explore why lupus therapies work for some, not others

The results should shed light not only on the mechanisms behind the disease, but more broadly on the workings of our immune system, especially how our bodies churn out and "train" key combat-ready immune cells, called B-cells.

8 Feb 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009